Muscle Preservation on GLP-1 Medications: What the Science Says You Must Do

Here is a number worth sitting with: clinical trial participants taking semaglutide or tirzepatide lost, on average, more than 10% of their total muscle mass over roughly 68 to 72 weeks of treatment. Research published in Obesity Reviews found that clinical trial participants receiving incretin-mimetic drugs for obesity treatment lost 10% or more of their muscle mass during 68- to 72-week interventions, approximately equivalent to 20 years of age-related muscle loss. — it is approximately equivalent to 20 years of age-related muscle loss, compressed into little more than a year. For men who got on a GLP-1 medication to get healthier, stronger, and leaner, that statistic should change the way they approach every single week of treatment.

GLP-1 receptor agonists — semaglutide, liraglutide, tirzepatide, and the newer agents coming down the pipeline — are genuinely impressive pharmacological tools. They reduce body weight by 15 to 24% in clinical trials, improve blood pressure, lower blood glucose, and reduce cardiovascular risk. But weight loss is not the same thing as fat loss, and this distinction is where most men using these medications get into trouble. The scale moves, the reflection in the mirror improves, and the assumption is that the work is done. What often goes unexamined is what is being lost alongside the fat — and the research is increasingly clear that lean mass losses on incretin-based therapies are rapid, significant, and comparable to a decade or more of normal aging.

This is not an argument against GLP-1 medications. It is an argument for using them intelligently — with the full support of resistance training, adequate protein, and targeted nutritional strategies that the medications themselves do not provide.

Why GLP-1 Medications Put Muscle at Risk

Understanding the mechanism matters here, because it explains why passive weight loss on any tool — medication, aggressive caloric restriction, or crash dieting — tends to erode muscle along with fat. GLP-1 receptor agonists work primarily by suppressing appetite and slowing gastric emptying, which translates into significantly reduced caloric intake. That caloric deficit is what drives weight loss. But the human body under caloric restriction does not selectively burn fat. It draws on available energy stores, and muscle tissue, being metabolically active, becomes a target. Recent findings suggest that up to 40% of total weight lost on GLP-1 receptor agonists can come from fat-free mass, which includes skeletal muscle — a figure that demands serious attention.

The biology runs deeper than simple caloric math. Emerging research points to the myostatin-activin-follistatin-inhibin system as a key regulator of what happens to muscle and bone during periods of negative energy balance. Myostatin and activins promote muscle degradation, while follistatin works to suppress their activity and protect lean mass. During the kind of sustained, significant caloric restriction that GLP-1 medications create, this system can tip toward breakdown rather than preservation — particularly in older men, those who are already sedentary, or those who are not consuming enough protein to support muscle protein synthesis. Add to this the gastrointestinal side effects that many men experience early in treatment — nausea, reduced appetite, food aversion — and the nutritional picture gets more complicated before it gets easier.

There is also a long-term consequence to consider. Muscle is not just about aesthetics or athletic performance. It is metabolically active tissue that supports insulin sensitivity, bone density, basal metabolic rate, and functional independence as men age. Loss of muscle during pharmacological weight loss increases the risk of sarcopenic obesity — a condition in which a man’s body fat percentage remains elevated even as total body weight drops, because lean mass has been depleted disproportionately. This is not a theoretical risk. It is a documented outcome in patients who undergo significant rapid weight loss without adequate countermeasures. And it creates a particularly dangerous setup for men who discontinue GLP-1 therapy: weight tends to return, but the muscle lost during treatment does not come back on its own.

The Two Pillars That Actually Protect Your Muscle

The research on this is not ambiguous. A 2025 review in Obesity Reviews identified two key factors that determine a person’s ability to maintain muscle mass during caloric restriction-induced weight loss: nutrition and physical exercise. Everything else — supplements, advanced pharmacology, recovery protocols — is secondary to getting these two fundamentals right. For men on GLP-1 medications, that means treating resistance training and protein intake not as optional add-ons, but as non-negotiable components of the treatment plan itself.

Resistance training earns its place at the top of this list because of what it signals to the body at a cellular level. When muscle fibers are subjected to mechanical load — through lifting, pushing, pulling, or carrying — the body receives a direct anabolic signal to maintain and build that tissue, even in a caloric deficit. Studies reviewed in Diabetes Care found that supervised resistance exercise training interventions lasting more than 10 weeks produced lean mass gains of approximately 3 kilograms and strength improvements of around 25% in both men and women — gains substantial enough to offset a significant portion of the lean mass losses associated with incretin therapy. The recommendation that follows from this evidence is specific: resistance training sessions should occur at least two to three times per week, with a focus on compound movements that recruit the largest muscle groups — squats, deadlifts, rows, presses, and loaded carries. Progressive overload, meaning the gradual increase of weight or volume over time, is what drives adaptation. Showing up and going through the motions with light weights will not generate the anabolic stimulus needed to counteract the catabolic environment of sustained caloric restriction.

Protein intake is the nutritional counterpart to that training stimulus. Without adequate dietary protein, the body cannot perform muscle protein synthesis at the rate needed to offset the breakdown that caloric restriction promotes. A 2025 joint advisory from four major medical organizations — including the American Society for Nutrition and the Obesity Medicine Association — specifically identified preserving muscle and bone mass through resistance training and appropriate diet as a clinical priority during GLP-1 therapy. The protein targets that align with current evidence for men in a caloric deficit hover around 1.6 to 2.2 grams per kilogram of body weight per day, with some research supporting the higher end of that range for men who are actively resistance training. The challenge for GLP-1 users is that the appetite suppression caused by these medications can make hitting protein targets genuinely difficult. Nausea and reduced hunger mean that total food intake drops — and if men are not deliberate about protein prioritization, carbohydrates and fats tend to crowd out the most muscle-protective macronutrient. The practical solution is to lead every meal with the protein source: eat the chicken, the eggs, the fish, or the Greek yogurt first, before anything else on the plate, when appetite is at its highest.

Beyond the protein itself, specific nutrients deserve attention. Current evidence suggests that branched-chain amino acids, creatine, leucine, omega-3 fatty acids, and vitamin D may each offer supportive benefits for muscle preservation in the context of GLP-1 therapy, particularly when dietary intake is insufficient. Creatine monohydrate, in particular, has one of the most robust evidence bases in all of sports nutrition — supporting strength, power output, and lean mass retention during resistance training. A dose of three to five grams per day requires no loading phase and carries an exceptional safety profile. Leucine, the branched-chain amino acid most directly associated with triggering muscle protein synthesis, is found in highest concentrations in whey protein, beef, chicken, and eggs — another reason why food quality matters as much as protein quantity. Vitamin D and omega-3 fatty acids both play roles in anti-inflammatory signaling and muscle function, and men who are eating less due to GLP-1-induced appetite suppression are at heightened risk of falling short on both.

The emerging pharmacological frontier is also worth a brief mention, though it remains largely investigational. Compounds like Bimagrumab, Trevogrumab, and Garetosmab — which inhibit activin and myostatin signaling — have shown early promise in preventing muscle loss while promoting fat loss, either alone or in combination with incretin receptor agonists. These agents represent a genuinely exciting direction for body composition medicine, but they are not yet available for routine clinical use, and their long-term safety profiles are still being established. For the practical purposes of men navigating GLP-1 therapy today, the fundamentals of training and nutrition remain the primary tools — and the good news is that those tools, applied consistently, are highly effective.

Building the Habit Stack That Makes This Work

The challenge with GLP-1 medications is not usually a knowledge problem — most men who ask their doctor about semaglutide or tirzepatide have done some reading. The challenge is a behavioral one. Appetite suppression reduces the motivation to eat intentionally. Fatigue, which is common early in treatment, reduces the motivation to train. And the rapid, visible results on the scale can create a false sense of progress that makes the unglamorous work of protecting muscle feel less urgent. The 2025 joint medical advisory specifically called for comprehensive baseline assessment of muscle strength, function, and body composition at the start of GLP-1 treatment — a recommendation that underscores how seriously the medical community is taking this issue. If your prescribing physician has not discussed resistance training and protein targets with you, that is a gap worth closing at your next appointment.

Practically, this means scheduling resistance training sessions the way you would schedule any other non-negotiable appointment. It means keeping a high-protein food source available at every meal — a container of cottage cheese, a bag of jerky, a pre-cooked batch of ground turkey — so that protein is always the path of least resistance. It means tracking protein intake, at least loosely, until the habit is established. And it means being patient with the process: resistance training interventions need more than ten weeks to generate meaningful lean mass gains, which means the investment is a long-term one, not a short-term fix.

The Takeaway

GLP-1 medications can be a powerful lever for men who need meaningful metabolic change. But they are not a complete solution — they are a tool that works best when surrounded by the right structure. The research is consistent: without deliberate resistance training and adequate protein intake, a significant portion of what you lose on these medications will be the muscle you cannot afford to give up. The men who come out of GLP-1 therapy leaner, stronger, and metabolically healthier are the ones who treat the medication as one component of a larger strategy — not the strategy itself. Build the training habit. Prioritize protein. Take the long view. The scale will handle itself.